Drug intelligence / Profile preview

HLP004

Development stage: Phase 2
Lead developer: Helus Pharma
Modality: Small Molecules
Administration: Intramuscular

Overview

HLP004 (formerly CYB004) is a proprietary, small-molecule deuterated dimethyltryptamine (DMT) compound being developed by Helus Pharma (formerly Cybin) for the treatment of Generalized Anxiety Disorder (GAD). As a novel serotonergic agonist, HLP004 primarily targets the 5-HT2A receptor to activate serotonin pathways believed to promote neuroplasticity. The drug is designed to offer potentially more convenient and patient-friendly dosing, including intramuscular administration, compared to traditional DMT. It is currently in Phase 2 clinical development, with topline safety and efficacy data expected in the first quarter of 2026.

Other names: deuterated dimethyltryptaminedeuterated DMTdeuterated N,N-dimethyltryptamine

Targets

HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on HLP004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLP004.

Explore the full profile